Summary & Overview
HCPCS G9706: Low (or very low) risk of recurrence, prostate cancer
HCPCS Level II code G9706 denotes a clinical determination of low or very low risk of recurrence in prostate cancer patients. Nationally, standardized use of this code supports consistent documentation of risk stratification, which can influence follow-up intensity, surveillance strategies, and quality measurement for prostate cancer care. The code captures an important clinical status that is relevant to oncology and urology practices, payers managing cancer care pathways, and programs tracking outcomes.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage context, and the clinical setting in which it is typically recorded. The publication outlines benchmarks and policy considerations tied to coding for prostate cancer risk categories, discusses implications for service utilization and documentation, and provides clinical context for how a “low or very low” recurrence risk is used in care planning.
This summary serves clinicians, billing professionals, and policy analysts seeking a national perspective on the role of G9706 in prostate cancer risk documentation and its relevance to quality measurement and care coordination.
Billing Code Overview
HCPCS Level II code G9706 describes Low (or very low) risk of recurrence, prostate cancer. This code is used to indicate a clinical assessment that a patient with prostate cancer has a low or very low probability of cancer recurrence following initial diagnosis and treatment.
-
Service type: Risk stratification/clinical risk assessment
-
Typical site of service: Oncology clinic or outpatient urology/oncology setting
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of localized prostate adenocarcinoma under active surveillance presents for routine follow-up. His most recent prostate-specific antigen (PSA) is stable and low, digital rectal exam is unremarkable, and prior biopsy and imaging demonstrated low (or very low) risk features (Gleason score ≤6, clinical stage T1–T2a, limited core involvement). The clinician documents the patient’s cancer as low (or very low) risk of recurrence and selects billing code G9706 to indicate this risk stratification for quality reporting or registry purposes.
Typical workflow: the urologist or radiation oncologist reviews recent PSA trends, pathology reports, and imaging; documents risk category in the medical record; updates treatment plan (continued surveillance or conservative management); and reports G9706 during the visit or as part of a quality registry submission or value-based program. Counseling and shared decision-making occur during the clinic visit; any procedural interventions (biopsy, imaging, or treatment) are scheduled based on clinical findings.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Rarely applicable; use if an associated service required substantially greater work (documentation required). |